Harnessing the full potential of phages to develop novel antimicrobial compounds
MEDEA Biopharma is a lead discovery biopharmaceutical company developing new generation of high precision personalized microorganisms to kill harmful bacteria by using bacteriophages. MEDEA Biopharma validates bacterial targets, discovers effective bacteriophages and enables scalable tailored applications in various industry fields.
Rüdiger Trojok, Dr. Elene Kakabadze, Giorgi Khubua and Alexander Skripnik founded MEDEA Biopharma in 2022 to revolutionize bacterial infection treatment and solve the antibiotic resistance issue.
Potential to tackle multiple fields by personalized bacteriophages of MEDEA Biopharma with different application modalities
Personalized bacteriophages in infectious diseases to kill AMR bacteria & reduce antibiotics.
Personalized cosmetics with safe, effective bacteriophages to kill harmful bacteria.
Bacteriophages as prophylactic antimicrobials supplementing antibiotics in food chain.
Bacteriophages as prophylactic antimicrobials supplementing antibiotics in agriculture chain.